Holen Sie sich die Stockscreener-App
83.51
2.07%
1.6804
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$81.83
Offen:
$82.24
24-Stunden-Volumen:
647.17K
Relative Volume:
0.29
Marktkapitalisierung:
$13.22B
Einnahmen:
$4.34B
Nettoeinkommen (Verlust:
$-965.00M
KGV:
-13.76
EPS:
-6.07
Netto-Cashflow:
$869.00M
1W Leistung:
-1.08%
1M Leistung:
+7.24%
6M Leistung:
-41.39%
1J Leistung:
-18.17%
1-Tages-Spanne:
$82.07
$83.91
1-Wochen-Bereich:
$78.79
$85.90
52-Wochen-Spanne:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Firmenname
Illumina Inc
Sektor
Branche
Telefon
(858) 202-4500
Adresse
5200 ILLUMINA WAY, SAN DIEGO, CA
Vergleichen Sie ILMN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
83.50 | 13.06B | 4.34B | -965.00M | 869.00M | -6.07 |
|
TMO
Thermo Fisher Scientific Inc
|
405.02 | 152.34B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
193.94 | 135.39B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
527.37 | 41.54B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
114.91 | 31.61B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
148.65 | 24.31B | 15.50B | 1.33B | 2.16B | 7.34 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-04 | Bestätigt | Citigroup | Neutral |
| 2025-02-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-02-10 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-11-12 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-08-28 | Hochstufung | Argus | Hold → Buy |
| 2024-08-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-11-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Eingeleitet | Bernstein | Underperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Neutral |
| 2023-01-25 | Herabstufung | Argus | Buy → Hold |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Perform |
| 2022-12-12 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-04 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-07-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Hochstufung | Stifel | Hold → Buy |
| 2022-01-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Underweight |
| 2020-12-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-10-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Herabstufung | Stifel | Buy → Hold |
| 2020-09-22 | Herabstufung | UBS | Buy → Neutral |
| 2020-09-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Illumina Inc Aktie (ILMN) Neueste Nachrichten
Microbiome Sequencing Market Outlook 2025-2029 | Affordable Sequencing Instruments Expand Market Access for Smaller Labs - Yahoo
Forensic Genomics Market Research 2025Global Trends, Opportunity, and Forecasts 2020-2030 - GlobeNewswire Inc.
Digital Genome Market Deep Research Report on AI-Driven DNA Analysis Trends | Illumina, Thermo Fisher Scientific - openPR.com
Cancer Profiling Market Is Booming So Rapidly 2025-2032 - openPR.com
Hereditary Testing MarketGlobal Industry Trends, Opportunity, and Forecast, 2020-2030: Key Players Like Illumina and Myriad Genetics Leading the Charge - Yahoo
Next-Gen RNA Sequencing Market | Personalized Medicine & Future - openPR.com
Gene Panel Market Projected to Witness Massive GrowthIllumina, Inc., Thermo Fisher Scientific - openPR.com
Illumina Connected Insights - Technology Networks
Illumina Inc (ILMN) Stock Price Down 3.31% on May 30 - GuruFocus
Genotyping Assay Market Deep Research Report Highlights Key AdvancementsIllumina, Thermo Fisher Scientific - openPR.com
Illumina’s PromoterAI unlocks rare disease clues in noncoding genome - statnews.com
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain? - Yahoo Finance
Epigenetics Market Analysis 2025-2033: Advances in DNA - openPR.com
Illumina introduces PromoterAI for rare disease diagnosis By Investing.com - Investing.com South Africa
Illumina Inc.: Tackling Global Headwinds With Strategic Market Diversification! - Smartkarma
Illumina, Inc. (ILMN) Unveils AI Breakthrough for Rare Disease Diagnosis - Insider Monkey
Illumina introduces PromoterAI for rare disease diagnosis - Investing.com Australia
Operating a speedy, high-tech NGS lab in remote Australia - Illumina
Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis - PR Newswire
Bioinformatics Market Detailed in New Research ReportThermo Fisher Scientific, Illumina - openPR.com
DNA giant Illumina spawned an ecosystem of competitors and customers - Endpoints News
Illumina widens access to cancer tests with Medicare and new CDx - Yahoo Finance
Patent Fight Breaks Out over Genetic Sequencing - Orthopedics This Week
Illumina at Bernstein Conference: Strategic Insights and Challenges - Investing.com
Transcript : Illumina, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-28-2025 02 - marketscreener.com
Stifel Affirms Buy Rating on Illumina (ILMN) Stock - MSN
Illumina Expands Clinical Oncology Portfolio Unlocking New Standard of Care and Access to Precision Therapies - marketscreener.com
Illumina Expands Clinical Oncology Portfolio Unlocking New Standard Of Care And Access To Precision Therapies - marketscreener.com
Gene Expression Software Market Growth Projected at CAGR of 7.8% - openPR.com
Lab-on-a-chip and Microarrays (Biochip) Market Generated - openPR.com
Illumina expands oncology portfolio with new FDA-approved test By Investing.com - Investing.com Canada
Illumina expands oncology portfolio with new FDA-approved test - Investing.com
Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies - PR Newswire
Stifel maintains Illumina stock buy rating, $135 target - Investing.com
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain? - Yahoo Finance
Illumina at ESHG 2025 - Illumina
Video: How researchers are moving multiomics forward with Illumina technology - Illumina
GC Genome plans $30M IPO to diversify genomic products, suppliers - BioWorld MedTech
Microfluidic Market Is Booming Worldwide | Agilent Technologies, Inc., Illumina, Inc., Perkinelmer, Inc. - openPR.com
DNA Forensic Solution Market Size, Share & Trend, Regional - openPR.com
Single Cell Genome Sequencing Market to Witness Massive Growth - openPR.com
Illumina’s SWOT analysis: genetic giant’s stock faces China headwinds By Investing.com - Investing.com Nigeria
Illumina’s SWOT analysis: genetic giant’s stock faces China headwinds - Investing.com
Cell-Free DNA Isolation and Extraction Market - GlobeNewswire Inc.
Cathie Wood Reiterates 'Profound' AI Application In Healthcare As Researchers Discover 'Cancer Survival Outcomes' By Facial Photograph Analysis: Here Are The Stocks That Could BenefitInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), Illumina (NASDAQ:IL - Benzinga
Life Sciences Tools & Services Stocks Q1 Recap: Benchmarking Illumina (NASDAQ:ILMN) - Yahoo Finance
Tumor Profiling Market May Set New Growth Story | Illumina Inc., - openPR.com
Illumina Approves Key Proposals at Annual Meeting - TipRanks
Genotyping Market to Reach $61.6 Billion, Globally, by 2033 - openPR.com
Customized CRISPR for KJ, 10x and Illumina Lawsuits, Regeneron Bags 23andMe - Genetic Engineering and Biotechnology News
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software - MSN
Finanzdaten der Illumina Inc-Aktie (ILMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.66%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):